A
Alcista
Alcista · 25%MDXH
$3.36
Precio del escenario
$0.207
-0.136 (-65.77%)Al cierre
Loading chart…
- Máximo
- 0.410
- Apertura
- 0.400
- Precio medio ponderado por volumen
- 0.27
- Volumen
- 17.31M
- Capitalización
- 64.67M
- Mínimo
- 0.186
- Importe
- 4.63M
- EV/EBITDA, TTM
- -22.55
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Análisis de IA of MDxHealth SA (MDXH)
VenderMDxHealth SA is not a good buy right now due to its extremely low RSI of 11.078, indicating oversold conditions, and a staggering year-to-date change of -93.98%. The company is facing significant operational challenges and risks of delisting from Nasdaq due to failing to meet the minimum market value requirement, which adds to the uncertainty surrounding its future performance.
Métricas de valoración
El PER previsto actual de MDxHealth SA (MDXH) es 27.70, frente a su media de 5 años de 5.17.
Escenarios de precio de Alphio AI para MDXH
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
9.508-21NASDAQ.COMMDxHealth Reports Strong Q2 Performance with Revenue Growth
9.508-21Yahoo FinanceMDxHealth Reports Strong Q2 2026 Earnings with Significant Revenue Growth
9.508-14NewsfilterNeOnc's Clinical Data Exceeds Expectations, Stock Price May Face Major Adjustment
7.007-27NASDAQ.COMMDxHealth Receives Nasdaq Notification on Minimum Bid Price Deficiency
7.007-24seekingalphaMdxhealth SA Receives Nasdaq Compliance Notification
Preguntas frecuentes sobre MDXH, respondidas por Alphio AI
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States. It operates in the Healthcare sector.
MDxHealth SA is not a good buy right now due to its extremely low RSI of 11.078, indicating oversold conditions, and a staggering year-to-date change of -93.98%. The company is facing significant operational challenges and risks of delisting from Nasdaq due to failing to meet the minimum market value requirement, which adds to the uncertainty surrounding its future performance.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.